Abstract
Background: Ovarian cancer is one of the most aggressive types of gynecologic cancers. Many patients have a relapse within two years after diagnosis and subsequent therapy. Among different genetic changes generally believed to be important for the development of cancer, TP53 is the most common mutation in the case of ovarian tumors.
Objective: Our work aims to analyze the outcomes of different comparisons based on the overall survival of ovarian cancer patients, the determination of TP53 status and the amount of p53 protein in tumor tissues.
Methods: We analyzed and compared a collective of 436 ovarian patients’ data. The extracted data include TP53 mutation status, p53 protein level and information on the overall survival. Values for p53 protein level in dependence of the TP53 mutation status were compared using the Independent Samples t-Test. Survival analyses were displayed by Kaplan- Meier plots, using the log-rank test to check for statistical significance.
Results: We have not found any statistically significant correlations between the determination of TP53 status or the amount of p53 protein in tumor tissues and the overall survival of ovarian cancer patients.
Conclusion: In ovarian tumors the determination of both the TP53 status as well as the p53 protein amount has only limited diagnostic importance.
Keywords: Ovarian cancer, tumor suppressors, TP53, p53, patient survival, prognostic laboratory parameters.
Current Medicinal Chemistry
Title:Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian Cancer
Volume: 29 Issue: 24
Author(s): Sebastian M. Klein, Maria Bozko, Astrid Toennießen, Nisar P. Malek and Przemyslaw Bozko*
Affiliation:
- Department of Internal Medicine I, Universitätsklinikum Tübingen, Tübingen, Germany
Keywords: Ovarian cancer, tumor suppressors, TP53, p53, patient survival, prognostic laboratory parameters.
Abstract:
Background: Ovarian cancer is one of the most aggressive types of gynecologic cancers. Many patients have a relapse within two years after diagnosis and subsequent therapy. Among different genetic changes generally believed to be important for the development of cancer, TP53 is the most common mutation in the case of ovarian tumors.
Objective: Our work aims to analyze the outcomes of different comparisons based on the overall survival of ovarian cancer patients, the determination of TP53 status and the amount of p53 protein in tumor tissues.
Methods: We analyzed and compared a collective of 436 ovarian patients’ data. The extracted data include TP53 mutation status, p53 protein level and information on the overall survival. Values for p53 protein level in dependence of the TP53 mutation status were compared using the Independent Samples t-Test. Survival analyses were displayed by Kaplan- Meier plots, using the log-rank test to check for statistical significance.
Results: We have not found any statistically significant correlations between the determination of TP53 status or the amount of p53 protein in tumor tissues and the overall survival of ovarian cancer patients.
Conclusion: In ovarian tumors the determination of both the TP53 status as well as the p53 protein amount has only limited diagnostic importance.
Export Options
About this article
Cite this article as:
Klein M. Sebastian, Bozko Maria, Toennießen Astrid, Malek P. Nisar and Bozko Przemyslaw*, Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian Cancer, Current Medicinal Chemistry 2022; 29 (24) . https://dx.doi.org/10.2174/0929867329666220112141211
DOI https://dx.doi.org/10.2174/0929867329666220112141211 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α7 nAChR in Airway Respiratory Epithelial Cells
Current Drug Targets Development of a Reproducible, Sensitive and Rapid Reversed Phase Chromatographic Method for the Estimation of Isotretinoin Incorporated in Bulk Drugs, Pharmaceutical Dosage Forms and Biological Matrix
Current Pharmaceutical Analysis Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry Evolutioninthe Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease - Order Slowly Rises from the Chaos
Current Pharmacogenomics Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Advances in Efficient Health Communication: Promoting Prevention and Detection of STDs
Current HIV Research Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Coffee and Depression: A Short Review of Literature
Current Pharmaceutical Design Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry Dental Caries and Vaccination Strategy against the Major Cariogenic Pathogen, Streptococcus mutans
Current Pharmaceutical Biotechnology Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry